9 Analysts Have This to Say About Genmab
Portfolio Pulse from Benzinga Insights
Genmab (NASDAQ:GMAB) received 9 analyst ratings in the last quarter, with 8 being bullish and 1 somewhat bearish. The average 12-month price target for GMAB is $48.33, with a high of $54.00 and a low of $32.00. This target has increased by 13.26% over the past month, indicating a positive sentiment among analysts towards the stock.
November 28, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab has received overwhelmingly bullish ratings from analysts, with 8 out of 9 ratings being positive and an increased average price target, suggesting a favorable outlook.
The high number of bullish ratings and the increase in the average price target over the past month suggest that analysts see potential for the stock to perform well in the short term. This positive sentiment is likely to influence investor perception and could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100